Fredrik Piehl, Professor of Neurology at the Department of Clinical Neuroscience at Karolinska Institutet and researcher at ...

Rituximab is a human/mouse chimeric IgG1κ antibody ... effect profile in more than 50,000 transplant recipients. In MS patients, daclizumab is currently thought to take its therapeutic effect ...

Impact of bone marrow involvement in patients with peripheral T-cell lymphoma undergoing autologous stem cell transplant. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This ...

No evidence for alteration in B cell cytokine profiles is available Evidence that rituximab affects T-cell activation by B cells includes reduced T-cell expression of HLA-DR, CD154 and CD69 ...

Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).